IsoRay Medical, Inc. Announces It Has Provided Seeds to Canada for Research Initiatives to Expand the Use of Cesium-131 for New Cancer Applications

Published: Jan 25, 2010

RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay, Inc. (AMEX: ISR) announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).

Back to news